Clinical utility of antigen carbohydrate 125 in heart failure

go back to reference Richards AM (2009) What we may expect from biomarkers in Heart Failure. Heart Fail Clin 5:463–470PubMedCrossRef Richards AM (2009) What we may expect from biomarkers in Heart Failure. Heart Fail Clin 5:463–470PubMedCrossRef

go back to reference Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148–2159PubMedCrossRef Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148–2159PubMedCrossRef

go back to reference Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949–952PubMedCrossRef Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949–952PubMedCrossRef

go back to reference Richards AM (2010) New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol 63:635–639PubMedCrossRef Richards AM (2010) New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol 63:635–639PubMedCrossRef

go back to reference Palazzuoli A, Masson S, Ronco C, Maisel A (2013) Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev. doi:10.1007/s10741-013-9391-x Palazzuoli A, Masson S, Ronco C, Maisel A (2013) Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev. doi:10.​1007/​s10741-013-9391-x

go back to reference Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408–2416PubMedCrossRefPubMedCentral Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408–2416PubMedCrossRefPubMedCentral

go back to reference Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P (1994) CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 47:263–265PubMedCrossRefPubMedCentral Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P (1994) CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 47:263–265PubMedCrossRefPubMedCentral

go back to reference Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL (1986) Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 46:6143–6148PubMed Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL (1986) Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 46:6143–6148PubMed

go back to reference Canney PA, Moore M, Wilkinson PM, James RD (1984) Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 50:765–769PubMedCrossRefPubMedCentral Canney PA, Moore M, Wilkinson PM, James RD (1984) Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 50:765–769PubMedCrossRefPubMedCentral

go back to reference Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T (2003) Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 10:150–154PubMedCrossRef Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T (2003) Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 10:150–154PubMedCrossRef

go back to reference Kui Wong N, Easton RL, Panico M, Sutton-Smith M, Morrison JC, Lattanzio FA, Morris HR, Clark GF, Dell A, Patankar MS (2003) Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 278:28619–28634PubMedCrossRef Kui Wong N, Easton RL, Panico M, Sutton-Smith M, Morrison JC, Lattanzio FA, Morris HR, Clark GF, Dell A, Patankar MS (2003) Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 278:28619–28634PubMedCrossRef

go back to reference Murdoch WJ, Van Kirk EA, Smedts AM (2006) Complement-inhibiting effect of ovarian cancer antigen CA-125. Cancer Lett 236:54–57PubMedCrossRef Murdoch WJ, Van Kirk EA, Smedts AM (2006) Complement-inhibiting effect of ovarian cancer antigen CA-125. Cancer Lett 236:54–57PubMedCrossRef

go back to reference Yoshimura M, Ihara Y, Ohnishi A, Ijuhin N, Nishiura T, Kanakura Y, Matsuzawa Y, Taniguchi N (1996) Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer Res 56:412–418PubMed Yoshimura M, Ihara Y, Ohnishi A, Ijuhin N, Nishiura T, Kanakura Y, Matsuzawa Y, Taniguchi N (1996) Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer Res 56:412–418PubMed

go back to reference Núñez J, Miñana G, González M, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Chorro FJ, Llàcer A, Miguel A (2011) Antigen carbohydrate 125 in heart failure: not just a surrogate for serosal effusions? Int J Cardiol 146:473–474PubMedCrossRef Núñez J, Miñana G, González M, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Chorro FJ, Llàcer A, Miguel A (2011) Antigen carbohydrate 125 in heart failure: not just a surrogate for serosal effusions? Int J Cardiol 146:473–474PubMedCrossRef

go back to reference Núñez J, Miñana G, Núñez E, Sanchis J (2011) Antigen carbohydrate 125 in heart failure: a promising clinical tool. Int J Cardiol 150:369–370PubMedCrossRef Núñez J, Miñana G, Núñez E, Sanchis J (2011) Antigen carbohydrate 125 in heart failure: a promising clinical tool. Int J Cardiol 150:369–370PubMedCrossRef

go back to reference Ege MR, Zorlu A, Yılmaz MB (2011) CA-125 and heart failure. Int J Cardiol 147:453–454PubMedCrossRef Ege MR, Zorlu A, Yılmaz MB (2011) CA-125 and heart failure. Int J Cardiol 147:453–454PubMedCrossRef

go back to reference Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24:172–175PubMedCrossRef Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24:172–175PubMedCrossRef

go back to reference Varol E, Ozaydin M, Dogan A, Kosar F (2005) Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7:840–843PubMedCrossRef Varol E, Ozaydin M, Dogan A, Kosar F (2005) Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7:840–843PubMedCrossRef

go back to reference Epiney M, Bertossa C, Weil A, Campana A, Bischof P (2000) CA125 production by the peritoneum: in vitro and in vivo studies. Hum Reprod 15:1261–1265PubMedCrossRef Epiney M, Bertossa C, Weil A, Campana A, Bischof P (2000) CA125 production by the peritoneum: in vitro and in vivo studies. Hum Reprod 15:1261–1265PubMedCrossRef

go back to reference Seo T, Ikeda Y, Onaka H, Hayashi T, Kawaguchi K, Kotake C, Toda T, Kobayashi K (1993) Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J 57:489–494PubMedCrossRef Seo T, Ikeda Y, Onaka H, Hayashi T, Kawaguchi K, Kotake C, Toda T, Kobayashi K (1993) Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J 57:489–494PubMedCrossRef

go back to reference Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E (2006) Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 8:270–274PubMedCrossRef Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E (2006) Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 8:270–274PubMedCrossRef

go back to reference Núñez J, Sanchis J, Bodí V, Fonarow GC, Núñez E, Bertomeu-González V, Miñana G, Consuegra L, Bosch MJ, Carratalá A, Chorro FJ, Llàcer A (2010) Improvement in risk stratification with the combination of the tumor marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 31:1752–1763PubMedCrossRef Núñez J, Sanchis J, Bodí V, Fonarow GC, Núñez E, Bertomeu-González V, Miñana G, Consuegra L, Bosch MJ, Carratalá A, Chorro FJ, Llàcer A (2010) Improvement in risk stratification with the combination of the tumor marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 31:1752–1763PubMedCrossRef

go back to reference Topatan B, Basaran A (2010) CA-125 and heart failure: déjà vu or “still to be seen”. Int J Cardiol 145:626–629PubMedCrossRef Topatan B, Basaran A (2010) CA-125 and heart failure: déjà vu or “still to be seen”. Int J Cardiol 145:626–629PubMedCrossRef

go back to reference Huang F, Chen J, Liu Y, Zhang K, Wang J, Huang H (2012) New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses 79:381–383PubMedCrossRef Huang F, Chen J, Liu Y, Zhang K, Wang J, Huang H (2012) New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses 79:381–383PubMedCrossRef

go back to reference Miñana G, Núñez J, Sanchis J, Bodí V, Núñez E, Llàcer A (2010) CA125 and immunoinflammatory activity in acute heart failure. Int J Cardiol 145:547–548PubMedCrossRef Miñana G, Núñez J, Sanchis J, Bodí V, Núñez E, Llàcer A (2010) CA125 and immunoinflammatory activity in acute heart failure. Int J Cardiol 145:547–548PubMedCrossRef

go back to reference Hamdy NM, Basaran A (2011) Relationship between pro-anti-inflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure. Med Sci Monit 17:CR174–CR179PubMedCrossRef Hamdy NM, Basaran A (2011) Relationship between pro-anti-inflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure. Med Sci Monit 17:CR174–CR179PubMedCrossRef

go back to reference Núñez J, González M, Miñana G, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Puchades MJ, Palau P, Merlos P, Llàcer A, Miguel A (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540–548PubMedCrossRef Núñez J, González M, Miñana G, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Puchades MJ, Palau P, Merlos P, Llàcer A, Miguel A (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540–548PubMedCrossRef

go back to reference Colombo PC, Jorde UP (2010) The active role of venous congestion in the pathophysiology of acute decompensated heart failure. Rev Esp Cardiol 63:5–8CrossRef Colombo PC, Jorde UP (2010) The active role of venous congestion in the pathophysiology of acute decompensated heart failure. Rev Esp Cardiol 63:5–8CrossRef

go back to reference Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G, European Society of Cardiology; European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine. Eur J Heart Fail 12:423–433PubMedCrossRef Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G, European Society of Cardiology; European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine. Eur J Heart Fail 12:423–433PubMedCrossRef

go back to reference Bonfils PK, Damgaard M, Taskiran M, Goetze JP, Norsk P, Gadsbøll N (2010) Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. Eur J Heart Fail 12:995–1001PubMedCrossRef Bonfils PK, Damgaard M, Taskiran M, Goetze JP, Norsk P, Gadsbøll N (2010) Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. Eur J Heart Fail 12:995–1001PubMedCrossRef

go back to reference Dibbs Z, Thornby J, White BG, Mann DL (1999) Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 33:1935–2012PubMedCrossRef Dibbs Z, Thornby J, White BG, Mann DL (1999) Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 33:1935–2012PubMedCrossRef

go back to reference Núñez J, Núñez E, Consuegra L, Sanchis J, Bodí V, Martínez-Brotons A, Bertomeu-González V, Robles R, Bosch MJ, Fácila L, Darmofal H, Llàcer A (2007) Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 93:716–721PubMedCrossRefPubMedCentral Núñez J, Núñez E, Consuegra L, Sanchis J, Bodí V, Martínez-Brotons A, Bertomeu-González V, Robles R, Bosch MJ, Fácila L, Darmofal H, Llàcer A (2007) Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 93:716–721PubMedCrossRefPubMedCentral

go back to reference D’Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L (2003) Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41:1805–1811PubMedCrossRef D’Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L (2003) Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41:1805–1811PubMedCrossRef

go back to reference Faggiano P, D’Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, Dei Cas L (2005) Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 7:57–61PubMedCrossRef Faggiano P, D’Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, Dei Cas L (2005) Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 7:57–61PubMedCrossRef

go back to reference Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, Kalkandi EM, Babalis DK (2005) The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7:199–203PubMedCrossRef Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, Kalkandi EM, Babalis DK (2005) The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7:199–203PubMedCrossRef

go back to reference Duman D, Palit F, Simsek E, Bilgehan K (2008) Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 10:556–559PubMedCrossRef Duman D, Palit F, Simsek E, Bilgehan K (2008) Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 10:556–559PubMedCrossRef

go back to reference Nägele H, Bahlo M, Klapdor R, Rödiger W (1999) Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 19:2531–2534PubMed Nägele H, Bahlo M, Klapdor R, Rödiger W (1999) Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 19:2531–2534PubMed

go back to reference Hung CL, Hung TC, Liu CC, Wu YJ, Kuo JY, Hou CJ, Yeh HI (2012) Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 110:993–1000PubMedCrossRef Hung CL, Hung TC, Liu CC, Wu YJ, Kuo JY, Hou CJ, Yeh HI (2012) Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 110:993–1000PubMedCrossRef

go back to reference Yilmaz MB, Zorlu A, Tandogan I (2011) Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol 149:80–82PubMedCrossRef Yilmaz MB, Zorlu A, Tandogan I (2011) Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol 149:80–82PubMedCrossRef

go back to reference Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W (1999) CA 125 and its relation to cardiac function. Am Heart J 137:1044–1049PubMedCrossRef Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W (1999) CA 125 and its relation to cardiac function. Am Heart J 137:1044–1049PubMedCrossRef

go back to reference Ordu S, Ozhan H, Alemdar R, Aydin M, Caglar O, Yuksel H, Kandis H (2012) Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication. Tex Heart Inst J 39:30–35PubMedPubMedCentral Ordu S, Ozhan H, Alemdar R, Aydin M, Caglar O, Yuksel H, Kandis H (2012) Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication. Tex Heart Inst J 39:30–35PubMedPubMedCentral

go back to reference Mansour IN, Napan S, Tarek Alahdab M, Stamos TD (2010) Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompensated heart failure. Congest Heart Fail 16:15–20PubMedCrossRef Mansour IN, Napan S, Tarek Alahdab M, Stamos TD (2010) Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompensated heart failure. Congest Heart Fail 16:15–20PubMedCrossRef

go back to reference Vizzardi E, D’Aloia A, Pezzali N, Bugatti S, Curnis A, Dei Cas L (2012) Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail 18:68–73PubMedCrossRef Vizzardi E, D’Aloia A, Pezzali N, Bugatti S, Curnis A, Dei Cas L (2012) Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail 18:68–73PubMedCrossRef

go back to reference Monteiro S, Franco F, Costa S, Monteiro P, Vieira H, Coelho L, Oliveira L, Providência LA (2010) Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 140:115–118PubMedCrossRef Monteiro S, Franco F, Costa S, Monteiro P, Vieira H, Coelho L, Oliveira L, Providência LA (2010) Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 140:115–118PubMedCrossRef

go back to reference Antonini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R, Piazza R, Cappelletti P, Rubin D, Cassin M, Faggiano P, Nicolosi GL (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128:406–412PubMedCrossRef Antonini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R, Piazza R, Cappelletti P, Rubin D, Cassin M, Faggiano P, Nicolosi GL (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128:406–412PubMedCrossRef

go back to reference Varol E, Yücel H, Arslan A, Ozaydın M, Erdoğan D, Doğan A (2012) Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars 40:309–315PubMedCrossRef Varol E, Yücel H, Arslan A, Ozaydın M, Erdoğan D, Doğan A (2012) Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars 40:309–315PubMedCrossRef

go back to reference Varol E, Ozaydin M, Altinbas A, Aslan SM, Dogan A, Dede O (2007) Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels 22:30–33PubMedCrossRef Varol E, Ozaydin M, Altinbas A, Aslan SM, Dogan A, Dede O (2007) Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels 22:30–33PubMedCrossRef

go back to reference Karaca O, Guler GB, Guler E, Gunes HM, Alizade E, Agus HZ, Gol G, Kahveci G, Esen O, Esen AM, Turkmen M (2012) Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation. Congest Heart Fail 18:144–150PubMedCrossRef Karaca O, Guler GB, Guler E, Gunes HM, Alizade E, Agus HZ, Gol G, Kahveci G, Esen O, Esen AM, Turkmen M (2012) Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation. Congest Heart Fail 18:144–150PubMedCrossRef

go back to reference Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC, Miñana G, Palau P, Bertomeu-González V, Carratalá A, Mainar L, Chorro FJ, Llàcer A (2012) CA125 and BNP serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol 159:21–28PubMedCrossRef Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC, Miñana G, Palau P, Bertomeu-González V, Carratalá A, Mainar L, Chorro FJ, Llàcer A (2012) CA125 and BNP serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol 159:21–28PubMedCrossRef

go back to reference Miñana Escrivá G, Núñez J, Sanchis J, Bodi V, Núñez E, Chorro FJ, Llàcer A (2012) Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission. Med Clin (Barc) 139:479–486CrossRef Miñana Escrivá G, Núñez J, Sanchis J, Bodi V, Núñez E, Chorro FJ, Llàcer A (2012) Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission. Med Clin (Barc) 139:479–486CrossRef

go back to reference Husser O, Nunez J, Nunez E, Holzamer A, Camboni D, Luchner A, Sanchis J, Bodi V, Riegger G, Schmid C, Hilker M, Hengstenberg C (2013) Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc Interv 6:487–496PubMedCrossRef Husser O, Nunez J, Nunez E, Holzamer A, Camboni D, Luchner A, Sanchis J, Bodi V, Riegger G, Schmid C, Hilker M, Hengstenberg C (2013) Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc Interv 6:487–496PubMedCrossRef

go back to reference Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial), (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003CrossRef Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial), (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003CrossRef

go back to reference Kubánek M, Goode KM, Lánská V, Clark AL, Cleland JG (2009) The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 11:367–377PubMedCrossRef Kubánek M, Goode KM, Lánská V, Clark AL, Cleland JG (2009) The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 11:367–377PubMedCrossRef

go back to reference Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H (1999) Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45:1695–1707PubMed Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H (1999) Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45:1695–1707PubMed

go back to reference O’Donoghue M, Braunwald E (2010) Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 7:13–20PubMedCrossRef O’Donoghue M, Braunwald E (2010) Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 7:13–20PubMedCrossRef

go back to reference Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248–2261PubMedCrossRef Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248–2261PubMedCrossRef

go back to reference Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G (2008) Effect of rosuvastatin in patients with chronic heart failure (the gissi-hf trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231–1239PubMedCrossRef Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G (2008) Effect of rosuvastatin in patients with chronic heart failure (the gissi-hf trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231–1239PubMedCrossRef

go back to reference McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis. Circulation 120:2188–2196PubMedCrossRef McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis. Circulation 120:2188–2196PubMedCrossRef

go back to reference Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, Fujimatsu D, Kobayashi Y, Inoue T, Node K, Komuro I, PEARL Study Investigators (2013) Effects of pitavastatin on Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 77:917–925PubMedCrossRef Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, Fujimatsu D, Kobayashi Y, Inoue T, Node K, Komuro I, PEARL Study Investigators (2013) Effects of pitavastatin on Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 77:917–925PubMedCrossRef

go back to reference Núñez J, Sanchis J, Núñez E, Fonarow GC, Bodí V, Bertomeu-González V, Miñana G, Palau P, Fácila L, Chorro FJ, Bertomeu-Martínez V, Llàcer A (2011) Benefits of statin therapy according to plasma antigen carbohydrate 125 following an admission for acute heart failure. Rev Esp Cardiol 64:1100–1108CrossRef Núñez J, Sanchis J, Núñez E, Fonarow GC, Bodí V, Bertomeu-González V, Miñana G, Palau P, Fácila L, Chorro FJ, Bertomeu-Martínez V, Llàcer A (2011) Benefits of statin therapy according to plasma antigen carbohydrate 125 following an admission for acute heart failure. Rev Esp Cardiol 64:1100–1108CrossRef

go back to reference McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869PubMedCrossRef

go back to reference Tsouli SG, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS (2008) Should a statin be prescribed to every patient with heart failure? Heart Fail Rev 13:211–225PubMedCrossRef Tsouli SG, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS (2008) Should a statin be prescribed to every patient with heart failure? Heart Fail Rev 13:211–225PubMedCrossRef

go back to reference Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, Ponikowski P, Davos CH, Banasiak W, Zardini P, Haass M, Senges J, Coats AJ, Poole-Wilson PA, Pitt B (2006) Statin use and survival in patients with chronic heart failure—results from two observational studies with 5200 patients. Int J Cardiol 112:234–242PubMedCrossRef Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, Ponikowski P, Davos CH, Banasiak W, Zardini P, Haass M, Senges J, Coats AJ, Poole-Wilson PA, Pitt B (2006) Statin use and survival in patients with chronic heart failure—results from two observational studies with 5200 patients. Int J Cardiol 112:234–242PubMedCrossRef

go back to reference McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity c-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (corona): a retrospective analysis. Circulation 120:2188–2196PubMedCrossRef McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity c-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (corona): a retrospective analysis. Circulation 120:2188–2196PubMedCrossRef

go back to reference Felker GM, O’Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56–62PubMedCrossRefPubMedCentral Felker GM, O’Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56–62PubMedCrossRefPubMedCentral

go back to reference Eshaghian S, Horwich TB, Fonarow GC (2009) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759–1764CrossRef Eshaghian S, Horwich TB, Fonarow GC (2009) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759–1764CrossRef

go back to reference Ahmed A, Husain A, Love TE, Gambassi G, Dell’Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439PubMedCrossRefPubMedCentral Ahmed A, Husain A, Love TE, Gambassi G, Dell’Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439PubMedCrossRefPubMedCentral

go back to reference Núñez J, Núñez E, Miñana G, Bodí V, Fonarow GC, Bertomeu-González V, Palau P, Merlos P, Ventura S, Chorro FJ, Llàcer P, Sanchis J (2012) Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail 14:974–984PubMedCrossRefPubMedCentral Núñez J, Núñez E, Miñana G, Bodí V, Fonarow GC, Bertomeu-González V, Palau P, Merlos P, Ventura S, Chorro FJ, Llàcer P, Sanchis J (2012) Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail 14:974–984PubMedCrossRefPubMedCentral

go back to reference Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589–596PubMedCrossRefPubMedCentral Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589–596PubMedCrossRefPubMedCentral

go back to reference Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren W, Voors AA, van Veldhuisen DJ (2011) Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 57:2233–2241PubMedCrossRef Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren W, Voors AA, van Veldhuisen DJ (2011) Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 57:2233–2241PubMedCrossRef

go back to reference van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58:127–138PubMedCrossRef van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58:127–138PubMedCrossRef

go back to reference Schmitter D, Cotter G, Voors AA (2013) Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev. doi:10.1007/s10741-013-9396-5 Schmitter D, Cotter G, Voors AA (2013) Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev. doi:10.​1007/​s10741-013-9396-5

go back to reference Gaggin HK, Januzzi JL Jr (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. doi:10.1016/j.bbadis.2012.12.014 Gaggin HK, Januzzi JL Jr (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. doi:10.​1016/​j.​bbadis.​2012.​12.​014

go back to reference Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P (2012) Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122:23–35PubMedCrossRef Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P (2012) Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122:23–35PubMedCrossRef

go back to reference Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P (2009) Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Cardiac Fail 15:256–266CrossRef Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P (2009) Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Cardiac Fail 15:256–266CrossRef

go back to reference Sherwi N, Merali S, Wong K (2012) Personalizing biomarker strategies in heart failure with galectin-3. Future Cardiol 8:885–894PubMedCrossRef Sherwi N, Merali S, Wong K (2012) Personalizing biomarker strategies in heart failure with galectin-3. Future Cardiol 8:885–894PubMedCrossRef

go back to reference Bhardwaj A, Januzzi JL Jr (2010) ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 10:459–464PubMedCrossRef Bhardwaj A, Januzzi JL Jr (2010) ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 10:459–464PubMedCrossRef